Compare Novo Nordisk A/S (NVO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $46.28 (market cap $207.85B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85.1. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VOOG | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $85.42 |
52-Week Low | $35.29 | $65.32 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
VOOG trades at $85.155, down 0.05% today, with a bullish technical signal driven by moving averages and strong trend momentum (ADX). The ETF recently hit a 52-week high, reflecting positive market sentiment. Recent news highlights institutional buying, such as Apella Capital increasing holdings by 463.2% in Q2 2026 (Defense World, August 7, 2026).
Outlook remains favorable due to growth stock exposure and low expense ratio (0.07%), but risks include tech concentration and overbought RSI levels. Analysts view VOOG as a core growth holding, though volatility from sector shifts poses a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
